Search Medical Condition
Please enter condition
Please choose location from dropdown

Neptune, New Jersey Clinical Trials

A listing of Neptune, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (102) clinical trials

A Safety Study of Growth Factor Use in Treatment With Brentuximab Vedotin Plus Chemotherapy

This study will evaluate the impact of granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with A+AVD on the incidence of febrile neutropenia, efficacy, and dose intensity in patients with advanced stage Hodgkin lymphoma. Patients will be treated using institutional standard of care practices for the majority of ...

Phase

8.56 miles

Learn More »

Study of PlasmaCap IG in Adults and Children With PIDD

The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of ...

Phase

8.61 miles

Learn More »

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Phase

8.61 miles

Learn More »

Pediatric Multicenter Study of REPEL-CV

- Efficacy at second sternotomy

Phase

8.61 miles

Learn More »

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma

Phase

8.61 miles

Learn More »

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Phase

8.7 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

This study is an international phase 3 randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg in patients with androgen-sensitive advanced prostate cancer who require at least 1 year (48 weeks) of continuous androgen deprivation therapy. Relugolix 120 mg orally once daily or leuprolide ...

Phase

8.7 miles

Learn More »

Study to Assess the Safety Tolerability Efficacy and PK of APL-2 in Patients With wAIHA or CAD

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

Phase

8.7 miles

Learn More »

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML

The Grb2 gene has been mapped to the human chromosome region 17q22-qter, a region that is duplicated in leukemias and solid tumors, which may result in an increased copy number of the Grb2 gene product. As Grb2 is important for the transformation of murine hematopoietic cells, and the proliferation of ...

Phase

8.7 miles

Learn More »

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

An evaluation of efficacy, as measured by progression-free survival (PFS) assessed by independent review and overall survival (OS), of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in patients with advanced HER2+ breast cancer who have received at least 2 prior lines of anti-HER2 directed therapy in the metastatic setting, ...

Phase

8.7 miles

Learn More »